Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2003 1
2004 5
2005 4
2006 2
2007 4
2008 4
2009 7
2010 8
2011 2
2012 8
2013 11
2014 12
2015 7
2016 8
2017 5
2018 7
2019 7
2020 8
2021 7
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 39477325

101 results

Results by year

Filters applied: . Clear all
Page 1
Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, Furukawa H, Hayashi H, Nakamura K, Inokuchi M, Nakagawara H, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fujimura T, Masakazu Y, Hirakawa K, Ohta T. Kinoshita J, et al. Oncol Rep. 2014 Jul;32(1):89-96. doi: 10.3892/or.2014.3210. Epub 2014 May 23. Oncol Rep. 2014. PMID: 24859429
Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.
Makinoya M, Miyatani K, Matsumi Y, Sakano Y, Shimizu S, Shishido Y, Hanaki T, Kihara K, Matsunaga T, Yamamoto M, Tokuyasu N, Takano S, Sakamoto T, Hasegawa T, Saito H, Nakayama Y, Osaki M, Okada F, Fujiwara Y. Makinoya M, et al. Sci Rep. 2024 May 2;14(1):10075. doi: 10.1038/s41598-024-60967-x. Sci Rep. 2024. PMID: 38698201 Free PMC article.
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K. Hirata K, et al. BMC Cancer. 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1. BMC Cancer. 2020. PMID: 32532230 Free PMC article.
101 results